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Introduction
A growing number of epidemiologic studies consis-
tently shows a protective effect of polyphenol-rich foods
(fruit, tea, wine, cocoa or chocolate…) against many dis-
eases 1–4. This evidence is supported by the results of nu-
merous studies conducted in animal models, with nutrition-
ally realistic levels of isolated flavonoids 5, 6, and in humans
with flavonoid-rich foods 1–4. The most famous so-called
French paradox, the lack of a positive correlation between a
high intake of saturated fat and the occurrence of coronary
heart disease is related at least partly to the consumption of
red wine 7, which is rich in flavonoids. Due to the variety of
pharmacological activities in the human body, flavonoids are
referred as “nutraceuticals” 8.
In spite of such extensive number of articles about health
benefits of flavonoids, further researches in this field are
broadly conducted. In this very moment, on PubMed more
than 58,000 references about flavonoids can be found. Since
flavonoids are the subject of our longtime research 9, our aim
was to give a personal account on the development of this field
through a retrospective of some basic data about flavonoids,
their pharmacological properties and mechanism of action. In
this review, special attention was paid to one of the most
promising bioactive bioflavonoids, hesperidin (Hesp).
About flavonoids
Flavonoids (flavus, the Latin word for yellow) or bio-
flavonoids, polyphenolic low weight secondary metabolites,
are present in great number of higher plant species, princi-
pally placed in fruit bark, seeds or flowers. For the time be-
ing, more than 8000 different flavonoids have been identi-
fied, and that number constantly increases 10. Starting from
1936, with the first article about flavonoids bioactivity 11,
numerous literature data were published about their structure
and characteristics primarily connected to antioxidative ac-
tivity.
Chemically, flavonoid molecules consist of carbon at-
oms assembled in two aromatic rings that are connected by a
three-carbon “bridge”, C6-C3-C6, thus forming a diphenyl-
propane structure with the central unit being a benzo-J-
pyrone (chromone). Multiple hydroxyl groups, sugar, oxy-
gen, or methyl groups are attached to this core structure. A
group of flavonoids is differentiated in several classes ac-
cording to the degrees of oxidation and unsaturation of the
heterocyclic C ring. The major flavonoid classes are: cate-
chins, dihydroxychalcones, chalcons, flavanones, flavanols,
flavones, isoflavones, anthocyanidols, aurones and flavonols.
Depending on the oxidation state of the heterocyclic ring,
flavonoids (in constricted sense) are classified as flavones,
flavanonols, flavonols and flavanones 12.
A considerable number of plant medicines contain fla-
vonoids, which have been reported by many authors as hav-
ing antibacterial 13, anti-inflammatory 14, antiallergic 15, an-
timutagenic 16, antiviral 17, antineoplastic 18, 19, anti-
thrombotic 20, 21, and coronary heart disease actions 22–25.
Overwhelmingly, pharmacological effects are related to anti-
oxidant activity of flavonoids, arising through their ability to
scavenge free radicals. When generated in excess, free radi-
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cals can damage biomolecules, and are therefore implicated
in the etiology of several diseases and ageing 26. Radical
scavenging by flavonoids occurs via electron donation from
the free hydroxyls on the flavonoid nucleus, with the forma-
tion of a less reactive flavonoid aroxyl radical stabilized by
resonance and therefore playing a moderate role in the
propagation of the radical-induced damages in biological
systems. Antioxidant activity of flavonoids correlates well
with their physiological function in vivo, because oxidative
stress is known to participate in the initial process of differ-
ent patho-physiological events. Literature data report that
flavonoids can prevent injury caused by free radicals by the
following mechanisms: direct scavenging of reactive oxygen
species (ROS), activation of antioxidant enzymes, metal
chelating activity, reduction of Į-tocopheryl radicals, inhibi-
tion of oxidases, mitigation of oxidative stress caused by ni-
tric oxide, increase in uric acid levels, increase in antioxidant
properties of low molecular antioxidants (27 and references
therein).
Besides direct free radical scavenging, flavonoids exert
antioxidant activity through interactions with the reduced
form of transition metals, primarily Cu(I) and Fe(II), as well
as Fe(III), which participate in free radical generating reac-
tions 28. Flavonoids may sequester metal ions by chelation,
thereby preventing the metal-mediated generation of free
radicals, and accordingly may protect the potential biological
targets from oxidative stress. Thus, the overall antioxidant
action of flavonoids appears to be a combination of a direct
reaction with free radical and chelating metal ions responsi-
ble for the production of ROS 29–38. We also investigated
more then 40 metal-flavonoid chelates, as summarized in our
review article 9.
Hesperidin
Chemical structure of hesperidin
Hesp, one of the most important flavonoids, is a low
molecular weight molecule (molecular weight 610.57 Da),
with the bruto formula C28H34O15, and belongs to the flava-
none class of flavonoids. Chemically, Hesp consists of agly-
cone (the forms lacking sugar moieties), hesperitin, and
sugar rutinoside: hesperetin-7-rutinoside, or IUPAC name:
(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-
3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-
yl]oxy-2,3-dihydrochromen-4-one. Hesp is represented by
the following chemical structure:
O
OH O
OH
OCH3
O9H21C12O
Sources of hesperidin
Hesp is the predominant flavonoid in citrus fruits, pri-
marily in sweet orange (in young immature oranges it ac-
counts for up to 14% of the fresh weight of the fruit 39) and
lemon, and consequently in juices made of these citruses.
The peel and membranous parts of these fruits have the high-
est Hesp concentrations, thus hand-squeezed juices contain
no detectable traces of Hesp 40. Commercial juices, on the
other hand, are rich in Hesp because the industrial processing
of fruits leads to juices being contaminated with the peel
constituents. According to the Code of Practice for evalua-
tion of quality and authenticity of fruit and vegetable juices,
published by the AIJN – European Fruit Juice Association,
special requirements for quality of citrus based juices (or-
anges, lemon and grapefruit) are that defined the Hesp con-
tent be as 250–700 mg/L 41.
Hesperidin pharmacokinetics
Although citrus fruits and juices are widely consumed
in the world, little information has been published on flava-
none bioavailability in humans. Hesp itself is absorbed from
the intestine intact as a glycoside. Its aglycone  hesperitin
appears in plasma 3 h after ingestion, reaching a peak be-
tween 5 and 7 h. The circulating forms of hesperetin are glu-
curonides (87%) and sulphoglucuronides (13%). For Hesp,
urinary excretion is nearly complete 24 h after the orange
juice ingestion and does not depend on the dose 42.
Hesperidin bioactivity
Although hesperidin has no usual structural elements
to suggest it as a good free radicals capturer and chelator,
the ability for chelating metal ions was confirmed in our
experiments 43–46. Several other investigators have exam-
ined Hesp antioxidant activity and radical scavenging prop-
erties using a variety of assay systems 47, 48.  Jovanovic et
al. 49 reports that Hesp reduces superoxide ions in electron
transfer plus concerted proton transfer reaction in vitro.
Further, Hesp was found to be effective in protecting lipo-
somes from UV-irradiation induced peroxidation, probably
by scavenging the oxygen free radicals generated by UV-
irradiation 50. Numerous studies confirmed a potent bioac-
tivity of Hesp, such as effects on the vascular system (re-
duces capillary permeability) 51, anti-inflammatory effects,
antioxidant effect, action on enzymes, antimicrobial activ-
ity (antibacterial, antifungal, antiviral, ...), anticarcinogenic
activity 52, cell aggregation inhibition, antiallergic effects,
UV protecting activity, radioprotection, and so on. In the
further text, more specific information about Hesp effects
on the cardiovascular system are given. Also, the literature
describing Hesp as promising protector against ionizing ra-
diation is assembled.
Hesperidin in prevention of (cardio)vascular diseases
In the review article by Garg et al. 53 the pharmacologi-
cal properties and medicinal uses of Hesp from the available
references were widely described. We emphasize some of
most essential Hesp activity.
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It has been presumed that Hesp could increase capillary
resistance thanks to its ability to inhibit hyaluronidase activ-
ity. Also, it has been confirmed that Hesp inhibits inflam-
matory processes in the ischaemia-induced hyperpermeabil-
ity, characteristic for venous stasis. Hesp capillary antihaem-
orrhagic activity has also been reported. Thus, Hesp supple-
mentation has been recommended for a wide range of blood
vessel disorders, such as fragility and permeability.
Investigations performed on rats showed improved an-
tihypercholesterolaemic activity of Hesp, exhibited as de-
creasing cholesterol, LDL, total lipids and triglyceride levels,
and increased HDL levels. Results of some studies indicate
the calcium channel blocker activity of Hesp.
Some studies have demonstrated antihypertensive and
diuretic effects of Hesp in rats following oral administration
of the drug at the dose of 200 mg/kg body weight, conclud-
ing that this hypotensive effect is caused by increased diure-
sis. On the other hand, it is well established that several
flavanones, including Hesp, exhibit influence on enzymes
such as protein kinase, lipooxygenase and cyclooxygenase.
The antihypertensive activity of Hesp might be due to influ-
ences on blood fluidity via enzymes. Further, various flavo-
noids are inhibitors of cyclic-AMP phosphodiesterase, so this
activity could be connected to their diuretic effect.
References dating from 2000 to the present time confirm
citrus fruit benefits on the vascular system. Thus, the con-
sumption of citrus fruit has been associated with a lower risk
of acute coronary events and stroke 54, 55. From clinical data,
citrus juice consumption reduces oxidative DNA damage in
blood cells 56 and improves plasma concentrations of inflam-
mation markers and oxidative stress 57–59. In addition, the con-
sumption of citrus juices improves lipemia in men with previ-
ous coronary bypass surgery 60. Furthermore, in hypertensive
subjects, the consumption of flavanone-rich grapefruit juice
exerts a significant beneficial effect on blood pressure 61.
The results of a very recent study published in Am J
Clin Nutr 62 are in agreement with numerous literature data.
In this study, the authors investigated the effect of orange
juice and its major flavonoid, Hesp, on microvascular reac-
tivity, blood pressure, and cardiovascular risk biomarkers
through both postprandial and chronic intervention studies.
During the three 4-week periods, 24 healthy, overweight men
(age 50–65) daily consumed 500 mL orange  juice, 500 mL
control drink plus Hesp (CDH), or 500 mL control drink plus
placebo (CDP). All measurements and blood collections
were performed in overnight-fasted subjects before and after
the 4-week treatment periods. The postprandial study was
conducted at the beginning of each experimental period. Dia-
stolic blood pressure was significantly lower after a 4-week
consumption of orange juice or CDH than after consumption
of CDP, whereas microvascular endothelium-related reactiv-
ity was not significantly affected when measured after an
overnight fast. However, both orange juice and CDH inges-
tion significantly improved postprandial microvascular en-
dothelial reactivity compared with CDP when measured at
the peak of plasma hesperetin concentration. As a conclusion
of this study, Hesp could be linked to the beneficial effect of
orange juice.
Although the consumption of Hesp juice rich food has
been reported to exert beneficial effects on some intermedi-
ate risk factors for CVD, such as LDL cholesterol, blood
pressure, and endothelial function 63, only a few clinical trials
have dealt with the oral administration of chemically pure
Hesp. Thus, the following study with 204 healthy partici-
pants evaluated the LDL-C–lowering efficacy of pure Hesp
in moderately hypercholesterolemic individuals (serum total
cholesterol (TC) concentration of 5.0–8.0 mmol/L) 64. The
study started with a 4 week preintervention period during
which the participants had to abstain from consuming citrus
fruits and their juices, food supplements containing hes-
peridin and/or naringin as well as plant sterol/stanol-enriched
foods, and other food products or supplements claiming to
lower cholesterol. During the 4-week intervention, the par-
ticipants applied the same dietary restrictions as during the
preintervention phase and consumed 4 capsules/d, providing
either placebo (cellulose) or the daily dose of 800 mg Hesp
or 500 mg naringin. Blood samples to measure serum lipids
were taken on 2 consecutive days at the beginning and the
end of the intervention phase. The intake of 800 mg/d Hesp
administered twice daily with main meals did not lower se-
rum TC and LDL-C in moderately hypercholesterolemic in-
dividuals. This outcome suggests that capsule format Hesp
exerts no cholesterol-lowering effect in humans.
Hesperidin as radioprotector
During the last several years, some researches were
conducted to utilise Hesp as a promising protector against
ionizing radiation (IR), since IR, as the part of our environ-
ment and in medical treatment, has been established as a
strong carcinogen.
IR causes cellular damage which is predominantly me-
diated through free radicals and resultant ROS 65. The inter-
action of IR with water, a major cellular constituent, results
in the generation of primary water radical species due to ra-
diolysis of water. These species react with molecules like
oxygen-producing secondary radicals (H2O2 and O2í), which
are highly reactive and could diffuse to vital cellular targets
like DNA, proteins, lipids and membrane, ultimately leading
to cancer and cell death 66.
Since free radicals play a major role in the initiation and
progression of IR induced toxicity, the use of antioxidants
either in the diet or as therapeutic agents might offer protec-
tion against radiation induced damage. A number of medici-
nal plants evaluated for their radioprotective efficacy have
shown protective effects against the damaging effects of IR.
The article of Nambai et al. 67 summeries the effects of vari-
ous phytochemicals on IR.
The development of effective radioprotectors is of great
importance in view of their potential application during both
planned radiation exposure (radiotherapy) and unplanned ra-
diation exposure (nuclear accidents, natural background radia-
tion emanating from the earth or other sources). Amifostine, a
thiol synthetic compound, is a powerful radioprotective agent
(marketed by MedImmune under the trade name Ethyol®).
However, due to its side effects and toxicity, the use of this
drug should be replaced with less toxic natural compounds 68.
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Since much research has been focused on the potential
use of flavonoids as free radical scavengers to prevent oxi-
dative damage 69, consequently several researches were con-
ducted to explore Hesp as radioprotector. The experiments
were performed either in animals (mouse and rats) or in vitro
(on human blood), since the study of radioprotective effects
is limited due to non-permission to irradiate healthy humans
for experimental research.  Experiments in animals were
performed using different graded doses (mg/kg body weight)
of Hesp administered orally via intragastric intubations for
several days prior to whole body radiation exposure with dif-
ferent doses (1–10 Gy).
Hosseinimehr and Nemati 70 investigated the radiopro-
cective effects of Hesp in mouse bone marrow cells by using
the micronucleus test for anticlastogenic and cell prolifera-
tion activity. They showed that Hesp has powerful protective
effects against DNA damage and on the decline in cell pro-
liferation induced by Ȗ-irradiation in mice by reducing the
frequency of the micronuclei.
Pradeep et al. 71 explored the hepatoprotective and anti-
oxidant effects of Hesp against Ȗ-irradiation induced oxida-
tive damage in the liver of male Sprague–Dawley rats. Expo-
sure to Ȗ-irradiation resulted in hepatocellular damage in a
dose-dependent manner, featuring a significantly decreased
body weight and liver weight and higher levels of serum
AST, ALT, ALP, LDH and Ȗ-GT levels and a simultaneous
decrease in their levels in the liver tissue. The Ȗ-irradiation
induced toxic effects were dramatically and dose-
dependently inhibited by Hesp treatment as observed by the
restoration in the altered levels of the marker enzymes, lipid
peroxidation, enzymatic and non-enzymatic antioxidants.
Kalpana et al. 72 investigated the radioprotective effi-
cacy of Hesp against x-ray radiation induced cellular damage
in the liver of Swiss albino mice. The results indicated that
radiation-induced decrease in the levels of endogenous anti-
oxidant enzymes and increase in lipid peroxidative index,
DNA damage and comet parameters were altered by pread-
ministration with the effective dose of Hesp which restored
the antioxidant status to near normal and decreased the levels
of lipid peroxidative index, DNA damage and comet pa-
rameters, which were confirmed by histopathological exami-
nations.
Besides these studies which have been performed to
evaluate natural products for their radioprotective effects in
animals, there are a few studies assessing the radioprotective
effects of natural origin compounds in human volunteers for
reducing the genetic side effects caused by IR. The radio-
protective effect of Hesp against genotoxicity induced by Ȗ-
irradiation has been investigated in vivo/in vitro in cultured
blood lymphocytes from human volunteers 73, 74. Peripheral
human blood samples were collected predose and after a sin-
gle oral ingestion of 1,000 mg of Daflon® (a dietary supple-
ment containing 50 mg of Hesp in 500 mg-tablet) corre-
sponding 100 mg of Hesp, then exposed in vitro to Ȗ-rays. A
significant increase (40%) in the incidence of micronuclei
after exposure to Ȗ-irradiation as compared to control unex-
posed samples was observed. After Daflon® administration, a
significant decrease in the incidence of micronuclei was ob-
served in comparison with similarly irradiated lymphocytes
collected before administration. These findings suggest a
possible application of Daflon® for the protection of human
lymphocytes from the genetic damage and side effects in-
duced by Ȗ-irradiation. Similar research was conducted by
Kalpana et al. 75 also showing that Hesp offers protection to
cultured human peripheral blood lymphocytes against radia-
tion induced cellular damage.
Dosage and administration
In numerous widely spread dietary supplements, Hesp
is present as Citrus complex of bioflavonoids, usually in a
combination with Vitamin C. In those kinds of products, the
content of total bioflavonoids is usually declared by the pro-
ducer, without the concentration of Hesp alone. For example,
in the preparation Vitamin C with citrus bioflavonoids &
Rose Hips®, the total citrus flavonoid content, according to
the factory declaration, was 751 mg per two capsules without
declaration for Hesp alone, but we found that each capsule
contains 260 mg of Hesp 76. In combination with a flavone
called diosmin, the tablets (trade name Daflon®) for treat-
ment of chronic venous insufficiency and hemorrhoids are
broadly available on the European market. A 500-mg dose of
this combination product is comprised of 50 mg of Hesp and
450 mg of diosmin. The doses for this type of supplement are
usually 500 mg to 2 g daily.
Conclusion
The beneficial effects of flavonoids on human health
are universally accepted nowadays. Citrus fruits and juices
with Hesp as major flavonoid remain one of the most read-
ily-available dietary sources for their intake. In dietary sup-
plements Hesp is usually present in a combination with vi-
tamin C. Epidemiological studies have shown an inverse as-
sociation between risk of cardiovascular diseases and intake
level of Hesp. Also, some experiments utilise Hesp as a
promising protector against IR. Further clinical trials are
needed to assess a more precise correlation between the Hesp
consumption and human health benefits.
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